Loading...
01/11 10:51
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Despite exceeding Q1 revenue and EBITDA guidance, concerns about declining gross margins due to tariffs, increased R&D spending, and macroeconomic pressures, such as higher churn and ASP pressure, neutralize the positive impact. The optimistic guidance and strategic initiatives like new product launches and loyalty programs offer potential upside, but uncertainties in execution and financial health create a balanced outlook.
Revenue $78.2 million, a decrease in some regions but driven by strong consumables revenue and operational improvements.
Adjusted EBITDA $13.9 million, above expectations due to cost control and margin expansion.
Gross Margin (GAAP) 62.8%, improved significantly year-over-year due to better demand planning and inventory management.
Adjusted Gross Margin 65.9%, up from 49.4% in the prior year period, driven by favorable mix and operational improvements.
Operating Expenses Decreased by 17.8% to $51.8 million, reflecting lower personnel-related expenses and improved cost management.
Device Revenue Declined by 36.5% year-over-year due to macroeconomic pressures affecting capital equipment purchases.
Consumable Sales $55.8 million, up 0.8% year-over-year, driven by growth in the Americas and EMEA, offset by declines in APAC.
Operating Loss $2.7 million, an improvement from a loss of $22.1 million in the prior year period.
Cash and Equivalents $212 million, down from $370 million at year-end 2024, due to debt restructuring and working capital investments.
Inventory Declined to $59.2 million from $69.1 million at year-end, reflecting improved demand planning and supply chain efficiency.
HydraFillic with Pep9 booster: Successfully launched and became the top-performing HydraFacial branded booster.
HydraFacial back bar product: Planned launch in Q4 2025 to boost in-office treatment results and provider revenue.
New retail skin care line: Debuting with a single hero product in Q4 2025, with more SKUs planned for 2026.
New scalp tips for Keravive and a lip tip: Expected launches in 2026 to enhance treatment outcomes.
Global expansion: Active devices increased to over 35,000 globally, up from 33,500 last year.
EMEA market: Increased booster adoption and expansion in the medical channel.
China market: Transitioned to a distributor model and centralized production in the U.S. to minimize tariff exposure.
Revenue and EBITDA: Achieved $78.2 million in revenue and $13.9 million in adjusted EBITDA, exceeding expectations.
Cost management: Reduced operating expenses by nearly 18% and lowered inventory.
Debt restructuring: Completed strategic debt restructuring, ending the quarter with $212 million in cash.
Gross margin improvement: GAAP gross margin at 62.8% and adjusted gross margin at 65.9%.
Razor-razor blade model: Consumables now account for over 70% of revenue, driving recurring revenue and margin expansion.
Sales organization: Strengthened with new leadership and a data-driven approach to pipeline management.
Provider partnerships: Enhanced business development tools and preparing to relaunch loyalty program in early 2026.
Macroeconomic pressures: Macroeconomic pressures are impacting capital equipment purchasing decisions, leading to a 36.5% year-over-year decline in global device revenue.
Regional revenue declines: Revenue in the Americas declined by 9.8%, APAC by 43.4%, and EMEA by 4.2%, with APAC being significantly affected by the transition to a distributor model in China.
China market transition: The transition from a direct business to a distributor model in China has led to revenue declines and potential tariff exposure for consumables sold in the region.
Tariff exposure: The company faces approximately $4 million in tariff exposure for the remainder of the year, particularly for consumables sold in China.
Device sales pressure: Device sales remain under pressure due to macroeconomic headwinds, despite efforts to improve performance through strategic execution and innovation.
Debt restructuring impact: The company incurred a decline in cash reserves due to a convertible note exchange and restructuring investments, which could impact financial flexibility.
Inventory challenges: While inventory levels have improved, the company still has 235 Elite fair market value devices remaining to sell, which could affect operational efficiency.
Revenue Guidance: The company has increased the low end of its full-year net sales guidance range to $285 million to $300 million.
Adjusted EBITDA Guidance: The company has increased both the top and bottom end of its adjusted EBITDA guidance range to $27 million to $35 million for the full year.
Q3 2025 Guidance: Net sales are expected to be between $65 million and $70 million, with adjusted EBITDA between $2 million and $4 million.
Innovation and Product Launches: The company plans to launch HydraFacial back bar products and a new retail skincare line in Q4 2025, with additional SKUs planned for 2026. Two new scalp tips for Keravive and a lip tip are expected to launch in 2026.
Market Trends and Growth: The specialty facial sector is expected to grow at a compounded annual growth rate of 7% through 2029, positioning the company to drive profitable growth.
Pricing Strategy: The company implemented a nearly 5% price increase across its consumables portfolio effective July 3, 2025, marking the first price increase in three years.
China Market Strategy: The company has transitioned its China business from a direct model to a distributor model, warehousing enough capital equipment inventory to satisfy expected demand for the remainder of the year.
The selected topic was not discussed during the call.
The earnings call reveals positive developments: increased revenue and EBITDA guidance, successful price hikes, and promising product launches. Although device sales face challenges, consumables show growth, and stabilization efforts are underway. The company's focus on innovation and strategic pricing, coupled with a positive market response to price increases, indicates a potential stock price uplift. However, management's lack of specific guidance for 2026 and ongoing macroeconomic pressures temper expectations, suggesting a moderate positive sentiment.
Despite exceeding Q1 revenue and EBITDA guidance, concerns about declining gross margins due to tariffs, increased R&D spending, and macroeconomic pressures, such as higher churn and ASP pressure, neutralize the positive impact. The optimistic guidance and strategic initiatives like new product launches and loyalty programs offer potential upside, but uncertainties in execution and financial health create a balanced outlook.
The earnings call presents a mixed outlook: strong financial metrics with increased revenue and improved EBITDA, but offset by macroeconomic pressures and tariff impacts. The Q&A reveals management's optimism about product launches and market leadership, yet concerns about luxury treatment demand and tariff costs persist. Despite improved gross margins and cash position, uncertainties in China and the global market, along with unclear guidance on tariffs, temper the positive financial results. These mixed factors suggest a neutral stock price movement over the next two weeks.
The earnings call highlights several concerning factors: a projected revenue decline, negative EBITDA guidance, and competitive pressures, particularly in international markets. Despite improvements in consumable sales and gross margin, the challenges in China, economic uncertainties, and lack of clarity on the distributor model raise red flags. The share repurchase program is a positive aspect, but overall, the negative guidance and risks outweigh the positives, suggesting a negative stock price movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
